Pharmacogenetic of Polymorphisms in HIV and Renal Transplanted Patients

JAUME ALBIOL CHIVA; DIEGO ENRIQUE KASSHUA; MICAELA FLORES; GERARDO CASTRO OCAMPO; JOSEP ESTEVE ROMERO; JUAN PERIS-VICENTE; SAMUEL CARDA BROCH; JESUS JAVIER IBORRA MILLET; EVA MATEO

Cannes

Simposio; 32nd International Symposium on Chromatography ISC; 2018

Pharmacogenetics predicts the individual response to a drug and its ultimate goal is patient healthcare. Some genetic variations can produce adverse reactions (hypersensitivity to the antirretroviral abacavir, toxicity to the antitumoral agents capecitabin and 5-F uracile) or ineffective treatments (acute reject to an organ transplantation due to a low bioavailavility of the immunosuppressive agent tacrolimus).The aim of the present study was to determine the genotype in patients treated with those drugs in the city of San Juan, and to calculate the prevalence of three genetic polymorphisms in the general population. The population consisted in 15 cancer patients, 15 HIV seropositive patients, 1 renal transplanted patient and 45 healthy volunteers. Patients and volunteers signed and informed consent. Genotypc and genic frequencies were evaluated by polymerase chain reaction (PCR).For the genetic variation HLA-B*57:01, genotype and allelic frequencies were 0.000 for seropositive patients and 0.022 for the general population. The prevalence was 2.00% for DYPD polymorphism genotype and allelic frequencies were 0.000 for cancer patients and healthy volunteers, which means that 100% of the studied individuals exhibited the normal homocygote variant G/G. The same frequencies were found for the CYP 3A5 polymorphism.Due to the low number of individuals studied, it was no possible to make any change of therapeutic regimen or dose. However, the prevalence obtained for HLA-B*57:01 was comparable with other reported results and it could be estimated a number of approximately 15,000 carriers of that genotype in San Juan. For those carriers, a genotyping study could diminish the appearance of adverse reactions to Abacavir.